Unboosted atazanavir with raltegravir has been investigated at 300mg twice daily showing frequent hyperbilirubinemia and selection of resistance-associated mutations.
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting
CALCAGNO, Andrea;
2017-01-01
Abstract
Unboosted atazanavir with raltegravir has been investigated at 300mg twice daily showing frequent hyperbilirubinemia and selection of resistance-associated mutations.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
ATV RAL Marinaro 2017 JCV.pdf
file disponibile solo agli amministratori
Licenza:
DRM non definito
Dimensione
836.39 kB
Formato
Adobe PDF
|
836.39 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
